Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-ketamine for Inflammatory Response in Septic Abdominal Surgery
NCT04873479Unknown
- Sponsor
- Tianjin Nankai Hospital
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine in sepsis (2 arms), sponsored by Tianjin Nankai Hospital. Primary endpoint: Incidence of postoperative pulmonary complications at 1 week. Status: unknown.
02
Drugs
esketamine
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT04873479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873479.